Last reviewed · How we verify

NCT06154551

Evaluation of the Levels of Salivary Paxillin Oral Premalignant and Malignant Lesions

Completed Last updated 4 December 2023
What this trial tests

trial testing Paxillin biomarker in Comparison of Salivary Paxillin Levels in OPMLs and OSCC to Healthy Subjects in 45 participants. Completed in 1 November 2023.

Timeline
29 November 2022
Primary endpoint
20 June 2023
1 November 2023

Quick facts

Lead sponsorCairo University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment45
Start date29 November 2022
Primary completion20 June 2023
Estimated completion1 November 2023
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Cairo University

Who can join

Adults 30 to 70, any sex, with Comparison of Salivary Paxillin Levels in OPMLs and OSCC to Healthy Subjects. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This investigation was carried out to analyze and compare the salivary paxillin levels between oral premalignant and malignant lesions (OPMLs), OSCC and the healthy controls in order to assess its potential role as a biomarker of oral cancer aiming for early diagnosis and better prognosis of OSCC. Methods: Forty-five patients, ranging in age from thirty to seventy-five, were divided into three groups: fifteen patients with OPMLs (lichen planus, leukoplakia), fifteen patients with OSCC, and fifteen controls who were in general well. Paxillin was identified in saliva samples by using an ELISA kit.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Evaluation of the levels of salivary paxillin in oral potentially malignant disorders and malignant lesions.
    Hussine AA, Selim K, Shaker O, Kamal Y. · · 2024 · cited 2× · PMID 39048985 · DOI 10.1186/s12903-024-04569-z

Verify or expand the search:

Other Cairo University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06154551.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing